Genmab A/S Announces Results of HUMAX-CD4(TM) Trial

22-Feb-2005

Genmab A/S announced additional encouraging duration of response data from one of its HuMax-CD4 (zanolimumab) phase II studies treating patients with mycosis fungoides (MF) a type of cutaneous T-cell lymphoma (CTCL). Data from all patients in the study showed a median response duration of more than 45 weeks (10.5 months). Furthermore, analysis of the time to response showed that 85% of the responding patients (11/13) obtained clinical response within 8 weeks. Additionally, previously released data was analyzed to assess the relation between dose and the serum concentration of HuMax-CD4 measured immediately before the next treatment (trough values). Increasing doses of HuMax-CD4 resulted in increased trough values.

"This latest set of duration of response data is very encouraging and indicates that HuMax-CD4 may be effective in treating CTCL patients with mycosis fungoides, especially at higher doses," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.

Other news from the department research and development

More news from our other portals

So close that even
molecules turn red...